Maintenance treatment for schizophrenia recommended
The Committee for Medicinal Products for Human Use has adopted a ‘positive opinion’ recommending paliperidone palmitate for the treatment of schizophrenia.
Paliperidone palmitate (TREVICTA) is an injection administered once every three months, which if approved, would provide the longest dosing interval available for an atypical antipsychotic medication.
The reduced administration required for this drug could improve the lives of people who are struggling with daily or monthly treatments.
‘The positive opinion for paliperidone palmitate 3-monthly injection is significant news for people with a diagnosis of schizophrenia in the UK because, if approved, it would enable them to focus on getting back to normal life with a much lower burden of medication,’ said Leonie Stein, Head of Medical Affairs at Janssen UK.
‘Poor adherence to treatment is a major trigger for relapse in schizophrenia, therefore the extended duration of treatment possible with paliperidone palmitate may provide helpful support to patients and reduce the need for intervention by their healthcare professional.’
A once monthly formulation of paliperidone palmitate (XEPLION®) is approved for the maintenance treatment of schizophrenia in Europe.